Aster DM Healthcare has secured no-objection clearances from both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) to merge with Quality Care India Ltd (QCIL), paving the way for deeper consolidation in India’s hospital sector.
Glimpse:
On October 6, 2025, both BSE and NSE issued no-objection letters supporting Aster DM Healthcare’s planned merger with QCIL. These regulatory clearances remove a major roadblock and bring the merger which will create one of India’s largest hospital chains closer to completion. Investor interest is expected to rise following the announcement.
Aster DM Healthcare has achieved a key regulatory milestone by receiving no-objection letters from the BSE and NSE for its proposed merger with Quality Care India Ltd (QCIL), with both approvals granted on October 6, 2025.
This step helps clear one of the significant procedural hurdles in the merger process and signals strong regulatory confidence in the transaction.
Earlier, Aster had already taken a strategic step by acquiring a 5% stake in QCIL via a share swap from BCP and Centella, at a transaction value of approximately ₹849 crore.
The acquisition was heralded as the first move toward the larger merger plan.
The merger proposal, initially inked in November 2024, envisions the newly combined entity being named Aster DM Quality Care. The merged network will bring together hospital brands such as Aster DM, CARE Hospitals, KIMSHEALTH, and Evercare. The consolidation plans project a network covering 38 hospitals with over 10,150 beds across 27 cities.
Under the swap ratio, Aster shareholders will hold about 57.3%, while QCIL’s shareholders will hold around 42.7% in the merged entity.
This merger has also received earlier competition clearance from the Competition Commission of India (CCI), enabling the parties to proceed on structural and shareholder fronts.
Business Standard
Analysts expect the move to drive operational synergies, cost efficiencies, and accelerated expansion in underserved regions.
With BSE/NSE clearances now secured, the merger is closer than ever to realization, contingent on final approvals from shareholders and courts, plus satisfying other customary conditions.
“These exchange-level no-objection letters are a strong signal of confidence they bring us one step closer to creating a unified healthcare platform that combines scale, quality, and accessibility.”
By
HB Team
Related News
